FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2949256841> ?p ?o ?g. }

• W2949256841 endingPage "635" @default.
• W2949256841 startingPage "635" @default.
• W2949256841 abstract "Background: Jonsdottir et al. (Blood Adv. 2017) recently suggested that, among the population of Sweden, a prior malignancy diagnosis (PMD) before the onset of MM increases the risk for developing a subsequent primary malignancy (SPM) after multiple myeloma (MM). Their analysis, however, did not account for death before the onset of a SPM as a competing risk. Therefore, their risk estimates might overestimate the magnitude of SPM development. Aims: To complement and extend on their observations, we revisited their analysis on the impact of a PMD on the first onset of a SPM in MM by employing competing risk regression. Methods: We identified all MM patients diagnosed between 1994–2012 from the nationwide population-based Netherlands Cancer Registry (NCR). PMDs and SPMs-excluding basal cell carcinomas-relative to MM were identified from the NCR. Synchronous malignancies diagnosed ≤6 months prior to or after MM diagnosis, and malignancies diagnosed from autopsies were excluded. SPMs were classified into subtypes according to the 3rd edition of the International Classification of Diseases for Oncology. We used competing risk regression as per Fine and Gray 3/4 with death before the onset of a SPM as a competing risk 3/4 to estimate sub-distribution hazard ratios (SHRs) with 95% confidence intervals (CIs) for the association between a PMD in MM patients and the development of a first SPM overall. These associations were also calculated for the subtypes as per SPM. We used Cox regression to calculate hazard ratios (HRs) with 95% CIs for the association between a PMD and the risk of mortality. All analyses were adjusted for baseline MM characteristics (i.e. sex, age, and period of diagnosis). All patients were followed from date of MM diagnosis to date of first SPM, death or end of follow-up (February 1, 2017), whichever came first. A P < 0.05 indicated statistical significance. Results: Our analytic cohort included 16,710 MM patients, of whom 1,760 (10.5%) had at least one PMD. Patients with a PMD were older at MM diagnosis, as compared to those without (median age 76 vs. 70; P < 0.001). At a median time of 3.8 years from MM diagnosis to first SPM (range 0.5–19.4), 138 of 1,760 (7.8%) MM patients with a PMD developed a SPM, as compared to 1,079 of 14,950 (7.2%) MM patients without (P = 0.341). Overall, there was no evidence for an increased rate of a first SPM in MM patients with a history of PMD, as compared to those without a history of PMD (adjusted SHR, 1.15; 95% CI, 0.96–1.38; P = 0.131; Table). However, subgroup analyses showed that there was an increased rate of breast cancer as first SPM in patients with a history of PMD (adjusted SHR, 2.45; 95% CI, 1.04–5.78; P = 0.040; Table) and melanoma of the skin (adjusted SHR, 3.05; 95% CI, 1.26–7.37; P = 0.014; Table). Finally, there was no statistically significant association of a PMD with the risk of mortality (adjusted HR, 1.04; 95% CI, 0.98–1.10; P = 0.177).Summary/Conclusion: In this population-based study, there was no apparent overall association between a history of a PMD and the development of a SPM among MM patients. However, subtype analyses showed increased rates for breast cancer and melanoma of the skin. Our results are not entirely in line with those of Jonsdottir et al. Of note, since we accounted for death before the onset of a SPM as a competing risk, our estimates are unlikely to be plagued by overestimation. Moreover, our results may guide cancer surveillance for early detection and appropriate management of SPMs, as MM survivorship is expected to increase due to continues therapeutic advances." @default.
• W2949256841 created "2019-06-27" @default.
• W2949256841 creator A5000879635 @default.
• W2949256841 creator A5001424327 @default.
• W2949256841 creator A5011515629 @default.
• W2949256841 creator A5015802614 @default.
• W2949256841 creator A5018517921 @default.
• W2949256841 creator A5029740585 @default.
• W2949256841 creator A5035290894 @default.
• W2949256841 creator A5040237587 @default.
• W2949256841 creator A5042546543 @default.
• W2949256841 creator A5058657986 @default.
• W2949256841 creator A5061763507 @default.
• W2949256841 creator A5068941457 @default.
• W2949256841 creator A5071448111 @default.
• W2949256841 creator A5076588623 @default.
• W2949256841 creator A5077876578 @default.
• W2949256841 creator A5085100871 @default.
• W2949256841 creator A5088441096 @default.
• W2949256841 creator A5090380142 @default.
• W2949256841 date "2019-06-01" @default.
• W2949256841 modified "2023-09-30" @default.
• W2949256841 title "PS1386 CARFILZOMIB AS PART OF A DOSE DENSE, LESS DOSE INTENSE TOTAL THERAPY APPROACH FOR HIGH RISK MYELOMA" @default.
• W2949256841 doi "https://doi.org/10.1097/01.hs9.0000563820.26261.85" @default.
• W2949256841 hasPublicationYear "2019" @default.
• W2949256841 type Work @default.
• W2949256841 sameAs 2949256841 @default.
• W2949256841 citedByCount "0" @default.
• W2949256841 crossrefType "journal-article" @default.
• W2949256841 hasAuthorship W2949256841A5000879635 @default.
• W2949256841 hasAuthorship W2949256841A5001424327 @default.
• W2949256841 hasAuthorship W2949256841A5011515629 @default.
• W2949256841 hasAuthorship W2949256841A5015802614 @default.
• W2949256841 hasAuthorship W2949256841A5018517921 @default.
• W2949256841 hasAuthorship W2949256841A5029740585 @default.
• W2949256841 hasAuthorship W2949256841A5035290894 @default.
• W2949256841 hasAuthorship W2949256841A5040237587 @default.
• W2949256841 hasAuthorship W2949256841A5042546543 @default.
• W2949256841 hasAuthorship W2949256841A5058657986 @default.
• W2949256841 hasAuthorship W2949256841A5061763507 @default.
• W2949256841 hasAuthorship W2949256841A5068941457 @default.
• W2949256841 hasAuthorship W2949256841A5071448111 @default.
• W2949256841 hasAuthorship W2949256841A5076588623 @default.
• W2949256841 hasAuthorship W2949256841A5077876578 @default.
• W2949256841 hasAuthorship W2949256841A5085100871 @default.
• W2949256841 hasAuthorship W2949256841A5088441096 @default.
• W2949256841 hasAuthorship W2949256841A5090380142 @default.
• W2949256841 hasBestOaLocation W29492568411 @default.
• W2949256841 hasConcept C120195587 @default.
• W2949256841 hasConcept C126322002 @default.
• W2949256841 hasConcept C143998085 @default.
• W2949256841 hasConcept C207103383 @default.
• W2949256841 hasConcept C2776364478 @default.
• W2949256841 hasConcept C2779399171 @default.
• W2949256841 hasConcept C2908647359 @default.
• W2949256841 hasConcept C44249647 @default.
• W2949256841 hasConcept C50382708 @default.
• W2949256841 hasConcept C71924100 @default.
• W2949256841 hasConcept C82789193 @default.
• W2949256841 hasConcept C99454951 @default.
• W2949256841 hasConceptScore W2949256841C120195587 @default.
• W2949256841 hasConceptScore W2949256841C126322002 @default.
• W2949256841 hasConceptScore W2949256841C143998085 @default.
• W2949256841 hasConceptScore W2949256841C207103383 @default.
• W2949256841 hasConceptScore W2949256841C2776364478 @default.
• W2949256841 hasConceptScore W2949256841C2779399171 @default.
• W2949256841 hasConceptScore W2949256841C2908647359 @default.
• W2949256841 hasConceptScore W2949256841C44249647 @default.
• W2949256841 hasConceptScore W2949256841C50382708 @default.
• W2949256841 hasConceptScore W2949256841C71924100 @default.
• W2949256841 hasConceptScore W2949256841C82789193 @default.
• W2949256841 hasConceptScore W2949256841C99454951 @default.
• W2949256841 hasIssue "S1" @default.
• W2949256841 hasLocation W29492568411 @default.
• W2949256841 hasLocation W29492568412 @default.
• W2949256841 hasOpenAccess W2949256841 @default.
• W2949256841 hasPrimaryLocation W29492568411 @default.
• W2949256841 hasRelatedWork W1727188710 @default.
• W2949256841 hasRelatedWork W2118215538 @default.
• W2949256841 hasRelatedWork W2119154902 @default.
• W2949256841 hasRelatedWork W2133235702 @default.
• W2949256841 hasRelatedWork W2135028155 @default.
• W2949256841 hasRelatedWork W2203903734 @default.
• W2949256841 hasRelatedWork W2343768426 @default.
• W2949256841 hasRelatedWork W2572837865 @default.
• W2949256841 hasRelatedWork W2787354007 @default.
• W2949256841 hasRelatedWork W2917746345 @default.
• W2949256841 hasVolume "3" @default.
• W2949256841 isParatext "false" @default.
• W2949256841 isRetracted "false" @default.
• W2949256841 magId "2949256841" @default.
• W2949256841 workType "article" @default.